Specialty Natural Products Public Company LimitedSET: SNPS🇹🇭 TH

Risk Management · 2025

Risk Management Policy & Plan

Policy & Plan Description

The Board of Directors has established policies and oversees risk management across all organizational units. The Board has assessed the following principal risks and emerging risks in all business processes:

Risks to the Company's Business Operations

Risk Register

Risk NameRisk CharacteristicsConsequencesManagement MeasuresRelated Risk Factors
Risk from Industry Competition

As consumers currently place greater importance on health and beauty care, this serves as a factor supporting the continuous growth of the health, beauty, and hygiene product manufacturing and distribution business. This has resulted in an increasing number of new operators—including product manufacturers and distributors, contract manufacturers, and importers or distributors of both small and large sizes—entering the health, beauty, and hygiene product market. This has intensified competition, with numerous substitute products under various brands having similar characteristics or properties, providing consumers with more choices in purchasing decisions, which may directly impact the market share, profitability, and long-term growth of the Company.

If the Group is unable to offer products that can compete with competitors in the market in terms of both quality and price, it may result in the Group losing customers, which may have a material adverse impact on the revenue and operating results of the Group.

The Group recognizes this risk and therefore places importance on continuous research and development (RD) of products, including increasing product variety, developing new products, and enhancing the performance of existing products, leveraging knowledge, experience, and expertise in herbs accumulated over more than 25 years, together with the application of technology and innovation in product formulation development to create distinctive products that are differentiated from those of other manufacturers and that can rapidly respond to changing customer demands in line with market trends and consumer behavior, in another focus on blue ocean market.

In addition, the Group places importance on quality control at every stage, from the selection of standardized raw material sources, through the production process, to product delivery, in order to maintain confidence and good relationships with existing customers, which is a critical factor in building competitive advantages that are difficult to replicate.

728 · Description: Volatility in the industry in which the company operates · Info category: STRATEGIC_RISK · 1714 · Description: Competition risk · Info category: STRATEGIC_RISK
Risk from ODM Customers Switching to Other Contract Manufacturers and/or Customers Discontinuing Existing Products with the Group

The Group’s main revenue derives from contract development and manufacturing of health, beauty, and hygiene products under customers’ brands (Original Design Manufacturer: ODM). In 2023–2025, the Group’s ODM revenue was as follows:

  • 2023: THB 220.76 million, representing 62.44% of total sales revenue

  • 2024: THB 301.24 million, representing 63.46% of total sales revenue

  • 2025: THB 341.61 million, representing 63.03% of total sales revenue

Customers place orders with the Group on a per-order basis without long-term purchase agreements. In addition, each product has a Product Life Cycle, requiring customers to continuously develop new products.

The Group may face the risk of ODM customers switching to other contract manufacturers and/or customers discontinuing existing products with the Group, which may have a material adverse impact on the revenue and operating results of the Group.

The Group recognizes this risk and therefore places importance on maintaining and developing good relationships with customers on a continuous basis, focusing on being a long-term business partner, while being able to rapidly offer new products aligned with market trends at appropriate prices to support customers’ competitiveness. This results in the Group receiving continuous trust and manufacturing engagements from customers.

At the same time, the Group implements a Customer Diversification strategy to increase the diversity of its customer base, reduce dependence on any single customer, and strengthen long-term revenue stability.

In addition, for products that customers commission SI to manufacture and that have been notified with the Food and Drug Administration (FDA) under SI’s name, such products must be manufactured according to the formula registered with SI only. Therefore, if such products become popular in the market, the likelihood of customers switching to other manufacturers is limited, as changing the manufacturing facility requires co-developing a new formula with the new manufacturer, which may result in product characteristics differing from the original formula.

733 · Description: Business operations of partners in the supply chain · Info category: STRATEGIC_RISK
Risk from Investment in New Products Under the Group’s Own Brands

The Company has extended its knowledge and expertise to the manufacturing and distribution of health, beauty, and hygiene products under its own brands (Own Brand), such as the distribution of “Colosure” dietary supplement under the Wellnova trademark, operated by WELL, the Company’s subsidiary, since late 2021. In 2025, the Company’s revenue from the distribution of such products increased from the previous year by 94%, reflecting the growth potential of the Company’s branded business.

The Group faces the risk that new products may not generate returns as expected, as the development and building of awareness for new products or brands requires high levels of investment in advertising, public relations, and sales promotion. However, in 2025, WELL was able to manage marketing expenses efficiently, resulting in a 49% decrease from the previous year, reflecting the ability to control costs alongside driving business growth.

The Company recognizes this risk. WELL has engage distributing partner which has expertise the planning and execution of marketing and sales g strategies to effectively reach target consumer groups.

In addition, the Group is in the process of conducting clinical trials of “Colosure” dietary supplement in collaboration with the Faculty of Medicine, Chiang Mai University, in preparation for registration as a medical food or food for special medical purposes which will help expand distribution channels through the medical sector in the future.

1716 · Description: New business risk · Info category: STRATEGIC_RISK
Risk from Dependence on R&D Personnel and Preservation of Manufacturing Formula Confidentiality

The Company places importance on extending the herbal knowledge accumulated over many years through the application of innovation and technology to develop standardized herbal extracts with distinctive characteristics and high efficacy, as well as to continuously develop health, beauty, and hygiene products. The R&D Department is a critical mechanism for creating innovation, gathering and applying knowledge from various research, to enhance the Company’s competitiveness.

However, the dependence on such specialized personnel may give rise to risk if key personnel are lost, which may cause the product development process to be disrupted, as well as increase the risk of leakage of manufacturing formulas or trade secrets to competitors, potentially impacting the Company’s competitive advantages and business interests in the long term.

If the Company is unable to retain its R&D personnel, or if knowledge or manufacturing formulas are leaked, it may result in the Company losing competitive advantages and impacting the continuity of the Group’s business operations.

The Company implements measures to retain R&D personnel with the organization in the long term through appropriate compensation and benefits, together with establishing measures to protect the Company’s critical knowledge, such as the execution of Non-Disclosure Agreements (NDAs) and the use of data storage systems with appropriate access restrictions. As a result, the turnover rate of R&D personnel decreased to 25% in 2024 and no resignations were recorded in 2025, reflecting the effectiveness of human resource management and the ability to control and reduce the risk of loss of the Company’s critical knowledge.

739 · Description: Shortage or reliance on skilled workers · Info category: OPERATIONAL_RISK
Risk from Procurement of Raw Materials with Adequate Quality and Sufficient Quantity

The Group’s primary raw materials used in production consist of herbal plants and standardized herbal extracts, which are classified as agricultural products. The quality and quantity of raw materials that can be harvested depend on multiple factors, such as climate conditions, cultivation area, and season, all of which are external factors beyond the Group’s control.

The Company may face the risk of volatility in the quantity and quality of herbal plants, which may result in the Group being unable to procure raw materials of adequate quality in sufficient quantities to meet demand, and being unable to deliver products to customers within the specified timeframe.

The Company procures raw materials through a network of farmer partners and community enterprises that have maintained business relationships for more than 10 years and are capable of delivering raw materials that meet the Company’s quality standards. The Company reserves herbal plant quantities in advance in line with the annual sales and production plans. In addition, for seasonal herbal raw materials that cannot be harvested year-round, the Group stores them in the form of concentrated crude extracts, which have a shelf life of up to 7 years, to ensure production continuity.

728 · Description: Volatility in the industry in which the company operates · Info category: STRATEGIC_RISK · 740 · Description: Shortage or fluctuation in pricing of raw materials or productive resources · Info category: OPERATIONAL_RISK · 1719 · Description: Climate change and disasters · Info category: STRATEGIC_RISK
Risk Relating to Product Quality and Safety

The Group’s products are intended for consumption and external use, which have a direct impact on the health and body of consumers. If damage can be proven to result from substandard manufacturing processes or contamination that fails to meet safety requirements, this may lead to product recalls, litigation, and severe reputational damage, which may materially impact consumer confidence and the financial position of the Group.

Consumers may file complaints or lawsuits seeking compensation from the Group, and there may be product recalls, production suspensions, or even revocation of relevant licenses, which may have a material adverse impact on the brand image, reputation, and financial performance of the Group.

The Company places the highest importance on product quality and safety by implementing effective quality control systems to strictly govern operations at every stage of the production process, through the QC/QA inspection system covering raw material procurement and inspection, storage, production, and product delivery. Operations comply with Good Manufacturing Practices and relevant international standards.

The Group has obtained multiple internationally recognized quality certifications, including ISO 9001:2015, ISO 22716:2007, FSSC 22000, GMP, HACCP, GHPs, GMP PIC/S, and GHPP. The Group is also in the process of preparing for ISO/IEC 17025 accreditation to upgrade its laboratory capabilities to international standards, which will further strengthen competitive advantages and support continuous development in both quality and the organization’s technical capabilities.

736 · Description: Damage to company image and reputation · Info category: STRATEGIC_RISK
Risk from Changes in Laws and Regulations Related to the Group’s Business Operations

The Group’s business operates under the laws, regulations, and oversight of the Ministry of Public Health and other relevant agencies both in Thailand and in countries where products are distributed. Business operations require obtaining, maintaining, and renewing various licenses, permits, and approvals from government authorities, such as factory operating licenses, food production and import licenses, herbal product licenses, production licenses (other than cultivation), hemp-related licenses, medical device establishment registration certificates, and other relevant licenses, each of which has specific conditions and timeframes to be complied with, and which may be subject to amendments to laws or criteria requiring the Group to take additional actions.

The Group may face the risk of delays in or inability to renew licenses, as well as the risk of being unable to comply with new laws or criteria in a timely manner, which may incur additional costs for system or operational process improvements, and may result in restricted product distribution channels if new requirements are not met, potentially having a material adverse impact on the Group’s future business operations and financial position.

The Company closely monitors news and guidance from regulatory authorities, and has established a compliance governance structure with the Quality Management Representative (QMR) and Regulatory Affairs (RA) departments responsible for overseeing and ensuring that the Group complies fully with relevant laws and regulations, including timely license renewals and continuous monitoring of changes in laws and regulations, to enable effective and timely preparation and adaptation, thereby supporting uninterrupted business operations.

756 · Description: Change in laws and regulations · Info category: COMPLIANCE_RISK
Risk from Dependence on Key Management in Business Operations

Assoc. Prof. Dr. Panvipa Krisdaphong and Dr. Theeraya Krisdaphong, who are major shareholders and key executives of the Company, have extensive experience and expertise in the herbal industry, resulting in deep knowledge and understanding of the business, as well as good relationships with customers and business partners both domestically and internationally. However, the operations and strategic decisions of the Group continue to be highly dependent on the knowledge and experience of these key executives.

Changes in key management may impact the continuity of management and policy execution of the Group in the future, and may also affect the confidence of business partners and investors, particularly in the event of sudden changes.

Assoc. Prof. Dr. Panvipa Krisdaphong, as the founder of the Company, and the family, which holds approximately 74% of issued shares as major shareholders, ensures that key management will continue to play an important role in determining the overall policies and direction of the Group on a continuous basis. The Group has systematic management in place, with a clearly defined organizational structure, responsibilities, and approval authorities for each management level, in order to decentralize decision-making and reduce dependence on any single individual.

In addition, the Group has established a Succession Plan, together with the development of Standardized Work systems, as well as policies for developing the capabilities of and creating incentives for executives and employees, to support business continuity and stable long-term growth.

738 · Description: Reliance on employees in key positions · Info category: OPERATIONAL_RISK

Risks to Securities Holders' Investment

Risk Register

Risk NameRisk CharacteristicsConsequencesManagement MeasuresRelated Risk Factors
Risk from the company having a major shareholder holding >50%

Currently, the Krisdaphong family collectively holds 300 million shares, representing 74% of the total issued and paid-up shares, which gives this shareholder group the power to control the Company and influence decision-making, whether in relation to the appointment of directors or the passing of resolutions on other matters requiring a majority vote of the shareholders’ meeting, except for matters that the law or the Group’s Articles of Association require a vote of not less than three-fourths of the shareholders’ meeting.

Other shareholders of the Company therefore face the risk of being unable to gather sufficient votes to scrutinize and counterbalance matters proposed by the major shareholder for consideration by the shareholders’ meeting.

The Company has appointed an Audit Committee to perform the function of auditing, considering, and screening to prevent transactions that may give rise to conflicts of interest in the future, and to ensure transparency in the Group’s operations. Furthermore, the Board of Directors structure comprises 4 independent directors (including the Chairman) out of a total of 8 directors, and 4 executive directors. Under the Public Company Act, in the event of a tie vote, the Chairman (who is an independent director), as the chairman of the meeting, has the right to cast an additional deciding vote. This Board structure ensures a balance of voting power in considering various matters and helps ensure that governance of management is appropriate and maximally effective.

2969 · Description: Risk of the company having a majority shareholder holding > 50% of shares · Info category: HOLDER_RISK
Contents